Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 3/20 | 0.50 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15721092 | 1.00 | SSTR4 (0.50) | SSTR4SSTR5BCHEACHEL3MBTL1 | |
| SCHEMBL4621769 | 1.00 | SSTR4 (0.50) | SSTR4SSTR5BCHEACHEL3MBTL1 | |
| SCHEMBL19575247 | 1.00 | SSTR4 (0.50) | SSTR4SSTR5BCHEACHEL3MBTL1 | |
| SCHEMBL7036228 | 0.98 | BCHE (0.49) | SSTR4SSTR5BCHEACHEL3MBTL1 | |
| SCHEMBL15721070 | 0.96 | BCHE (0.53) | SSTR4SSTR5BCHEACHEL3MBTL1 | |
| Bromide SCHEMBL28007848 | 0.95 | BCHE (0.53) | SSTR4SSTR5BCHEACHEL3MBTL1 | |
| SCHEMBL15721118 | 0.95 | BCHE (0.55) | SSTR4SSTR5BCHEACHEL3MBTL1 | |
| SCHEMBL15721151 | 0.95 | BCHE (0.55) | SSTR4SSTR5BCHEACHEL3MBTL1 | |
| SCHEMBL15721150 | 0.93 | SSTR4 (0.49) | SSTR4SSTR5BCHEACHEL3MBTL1 | |
| SCHEMBL19132634 | 0.91 | BCHE (0.53) | SSTR4SSTR5BCHEACHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630725-B1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-29 | — | — | EP | disclosed |
| US-11713297-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-11713297-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-11713297-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-11306058-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20220002245-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-01-06 | — | — | US | disclosed |
| US-20220002245-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-01-06 | — | — | US | disclosed |
| US-20200140385-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-07 | — | — | US | disclosed |
| US-20200140385-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-07 | — | — | US | disclosed |
| EP-3630725-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | Idorsia Pharmaceuticals Ltd (CH) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018220131-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713297-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | MGAM, UGCG, UGDH | SSTR4 3042/4885SSTR5 2160/4885BCHE 924/4885 |
| US-20200140385-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | MGAM, UGCG, UGDH | SSTR4 3042/4885SSTR5 2160/4885BCHE 924/4885 |
| US-11306058-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | MGAM, UGCG, UGDH | SSTR4 3042/4885SSTR5 2160/4885BCHE 924/4885 |
| US-20220002245-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | MGAM, UGCG, UGDH | SSTR4 3042/4885SSTR5 2160/4885BCHE 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.